QQQ   304.10 (-1.64%)
AAPL   120.13 (-1.58%)
MSFT   226.73 (-0.36%)
FB   257.64 (+0.87%)
GOOGL   2,033.93 (+1.12%)
TSLA   621.44 (-4.86%)
AMZN   2,977.57 (-0.91%)
NVDA   494.81 (-3.39%)
BABA   230.50 (-2.44%)
CGC   31.01 (-6.71%)
GE   13.57 (+0.97%)
MU   84.33 (-5.36%)
NIO   39.28 (-5.42%)
AMD   77.75 (-3.85%)
T   28.92 (+0.70%)
F   11.93 (-1.97%)
ACB   9.82 (-6.12%)
DIS   188.03 (-2.20%)
BA   224.71 (-1.68%)
NFLX   511.29 (-1.81%)
BAC   36.50 (+0.72%)
QQQ   304.10 (-1.64%)
AAPL   120.13 (-1.58%)
MSFT   226.73 (-0.36%)
FB   257.64 (+0.87%)
GOOGL   2,033.93 (+1.12%)
TSLA   621.44 (-4.86%)
AMZN   2,977.57 (-0.91%)
NVDA   494.81 (-3.39%)
BABA   230.50 (-2.44%)
CGC   31.01 (-6.71%)
GE   13.57 (+0.97%)
MU   84.33 (-5.36%)
NIO   39.28 (-5.42%)
AMD   77.75 (-3.85%)
T   28.92 (+0.70%)
F   11.93 (-1.97%)
ACB   9.82 (-6.12%)
DIS   188.03 (-2.20%)
BA   224.71 (-1.68%)
NFLX   511.29 (-1.81%)
BAC   36.50 (+0.72%)
QQQ   304.10 (-1.64%)
AAPL   120.13 (-1.58%)
MSFT   226.73 (-0.36%)
FB   257.64 (+0.87%)
GOOGL   2,033.93 (+1.12%)
TSLA   621.44 (-4.86%)
AMZN   2,977.57 (-0.91%)
NVDA   494.81 (-3.39%)
BABA   230.50 (-2.44%)
CGC   31.01 (-6.71%)
GE   13.57 (+0.97%)
MU   84.33 (-5.36%)
NIO   39.28 (-5.42%)
AMD   77.75 (-3.85%)
T   28.92 (+0.70%)
F   11.93 (-1.97%)
ACB   9.82 (-6.12%)
DIS   188.03 (-2.20%)
BA   224.71 (-1.68%)
NFLX   511.29 (-1.81%)
BAC   36.50 (+0.72%)
QQQ   304.10 (-1.64%)
AAPL   120.13 (-1.58%)
MSFT   226.73 (-0.36%)
FB   257.64 (+0.87%)
GOOGL   2,033.93 (+1.12%)
TSLA   621.44 (-4.86%)
AMZN   2,977.57 (-0.91%)
NVDA   494.81 (-3.39%)
BABA   230.50 (-2.44%)
CGC   31.01 (-6.71%)
GE   13.57 (+0.97%)
MU   84.33 (-5.36%)
NIO   39.28 (-5.42%)
AMD   77.75 (-3.85%)
T   28.92 (+0.70%)
F   11.93 (-1.97%)
ACB   9.82 (-6.12%)
DIS   188.03 (-2.20%)
BA   224.71 (-1.68%)
NFLX   511.29 (-1.81%)
BAC   36.50 (+0.72%)
Log in
NASDAQ:SAGE

Sage Therapeutics Competitors

$70.65
-5.52 (-7.25 %)
(As of 03/4/2021 12:00 AM ET)
Add
Compare
Today's Range
$69.32
Now: $70.65
$75.13
50-Day Range
$76.17
MA: $84.70
$96.76
52-Week Range
$25.01
Now: $70.65
$98.39
Volume844,692 shs
Average Volume509,513 shs
Market Capitalization$4.12 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.23

Competitors

Sage Therapeutics (NASDAQ:SAGE) Vs. RPRX, ALNY, CVAC, ELAN, BMRN, and ZLAB

Should you be buying SAGE stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Sage Therapeutics, including Royalty Pharma (RPRX), Alnylam Pharmaceuticals (ALNY), CureVac (CVAC), Elanco Animal Health (ELAN), BioMarin Pharmaceutical (BMRN), and Zai Lab (ZLAB).

Royalty Pharma (NASDAQ:RPRX) and Sage Therapeutics (NASDAQ:SAGE) are both finance companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Royalty Pharma and Sage Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Royalty Pharma05402.44
Sage Therapeutics010702.41

Royalty Pharma presently has a consensus price target of $51.8750, indicating a potential upside of 22.52%. Sage Therapeutics has a consensus price target of $80.50, indicating a potential upside of 13.94%. Given Royalty Pharma's stronger consensus rating and higher probable upside, equities analysts plainly believe Royalty Pharma is more favorable than Sage Therapeutics.

Earnings and Valuation

This table compares Royalty Pharma and Sage Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Royalty PharmaN/AN/AN/AN/AN/A
Sage Therapeutics$6.87 million600.39$-680,240,000.00($13.38)-5.28

Royalty Pharma has higher earnings, but lower revenue than Sage Therapeutics.

Profitability

This table compares Royalty Pharma and Sage Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Royalty PharmaN/AN/AN/A
Sage Therapeutics-7,706.84%-63.81%-56.64%

Institutional and Insider Ownership

40.9% of Royalty Pharma shares are held by institutional investors. 2.5% of Royalty Pharma shares are held by insiders. Comparatively, 4.8% of Sage Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Royalty Pharma beats Sage Therapeutics on 6 of the 9 factors compared between the two stocks.

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Sage Therapeutics (NASDAQ:SAGE) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

Volatility & Risk

Alnylam Pharmaceuticals has a beta of 1.47, meaning that its share price is 47% more volatile than the S&P 500. Comparatively, Sage Therapeutics has a beta of 2.23, meaning that its share price is 123% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and price targets for Alnylam Pharmaceuticals and Sage Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alnylam Pharmaceuticals19902.42
Sage Therapeutics010702.41

Alnylam Pharmaceuticals presently has a consensus price target of $163.4211, indicating a potential upside of 18.96%. Sage Therapeutics has a consensus price target of $80.50, indicating a potential upside of 13.94%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Alnylam Pharmaceuticals is more favorable than Sage Therapeutics.

Earnings & Valuation

This table compares Alnylam Pharmaceuticals and Sage Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alnylam Pharmaceuticals$219.75 million73.14$-886,120,000.00($8.11)-16.94
Sage Therapeutics$6.87 million600.39$-680,240,000.00($13.38)-5.28

Sage Therapeutics has lower revenue, but higher earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Sage Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Alnylam Pharmaceuticals and Sage Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alnylam Pharmaceuticals-222.19%-65.96%-31.38%
Sage Therapeutics-7,706.84%-63.81%-56.64%

Institutional & Insider Ownership

92.4% of Alnylam Pharmaceuticals shares are held by institutional investors. 3.5% of Alnylam Pharmaceuticals shares are held by insiders. Comparatively, 4.8% of Sage Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Alnylam Pharmaceuticals beats Sage Therapeutics on 8 of the 14 factors compared between the two stocks.

CureVac (NASDAQ:CVAC) and Sage Therapeutics (NASDAQ:SAGE) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

Analyst Recommendations

This is a summary of recent ratings and price targets for CureVac and Sage Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CureVac11202.25
Sage Therapeutics010702.41

CureVac presently has a consensus price target of $58.3333, indicating a potential downside of 28.28%. Sage Therapeutics has a consensus price target of $80.50, indicating a potential upside of 13.94%. Given Sage Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Sage Therapeutics is more favorable than CureVac.

Earnings & Valuation

This table compares CureVac and Sage Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CureVacN/AN/AN/AN/AN/A
Sage Therapeutics$6.87 million600.39$-680,240,000.00($13.38)-5.28

CureVac has higher earnings, but lower revenue than Sage Therapeutics.

Profitability

This table compares CureVac and Sage Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CureVacN/AN/AN/A
Sage Therapeutics-7,706.84%-63.81%-56.64%

Institutional & Insider Ownership

4.3% of CureVac shares are held by institutional investors. 4.8% of Sage Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Sage Therapeutics beats CureVac on 5 of the 9 factors compared between the two stocks.

Elanco Animal Health (NYSE:ELAN) and Sage Therapeutics (NASDAQ:SAGE) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

Volatility & Risk

Elanco Animal Health has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500. Comparatively, Sage Therapeutics has a beta of 2.23, meaning that its share price is 123% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and price targets for Elanco Animal Health and Sage Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Elanco Animal Health22602.40
Sage Therapeutics010702.41

Elanco Animal Health presently has a consensus price target of $30.50, indicating a potential downside of 1.39%. Sage Therapeutics has a consensus price target of $80.50, indicating a potential upside of 13.94%. Given Sage Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Sage Therapeutics is more favorable than Elanco Animal Health.

Earnings & Valuation

This table compares Elanco Animal Health and Sage Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Elanco Animal Health$3.07 billion4.76$67.90 million$1.0629.18
Sage Therapeutics$6.87 million600.39$-680,240,000.00($13.38)-5.28

Elanco Animal Health has higher revenue and earnings than Sage Therapeutics. Sage Therapeutics is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Elanco Animal Health and Sage Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Elanco Animal Health-8.45%3.43%2.04%
Sage Therapeutics-7,706.84%-63.81%-56.64%

Institutional & Insider Ownership

86.8% of Elanco Animal Health shares are held by institutional investors. 0.1% of Elanco Animal Health shares are held by insiders. Comparatively, 4.8% of Sage Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

BioMarin Pharmaceutical (NASDAQ:BMRN) and Sage Therapeutics (NASDAQ:SAGE) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

Institutional & Insider Ownership

97.7% of BioMarin Pharmaceutical shares are held by institutional investors. 2.2% of BioMarin Pharmaceutical shares are held by insiders. Comparatively, 4.8% of Sage Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares BioMarin Pharmaceutical and Sage Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioMarin Pharmaceutical$1.70 billion8.15$-23,850,000.00$0.071,090.71
Sage Therapeutics$6.87 million600.39$-680,240,000.00($13.38)-5.28

BioMarin Pharmaceutical has higher revenue and earnings than Sage Therapeutics. Sage Therapeutics is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for BioMarin Pharmaceutical and Sage Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioMarin Pharmaceutical081102.58
Sage Therapeutics010702.41

BioMarin Pharmaceutical presently has a consensus price target of $117.3636, indicating a potential upside of 53.72%. Sage Therapeutics has a consensus price target of $80.50, indicating a potential upside of 13.94%. Given BioMarin Pharmaceutical's stronger consensus rating and higher probable upside, equities research analysts plainly believe BioMarin Pharmaceutical is more favorable than Sage Therapeutics.

Profitability

This table compares BioMarin Pharmaceutical and Sage Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioMarin Pharmaceutical45.74%4.34%2.84%
Sage Therapeutics-7,706.84%-63.81%-56.64%

Volatility & Risk

BioMarin Pharmaceutical has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500. Comparatively, Sage Therapeutics has a beta of 2.23, meaning that its share price is 123% more volatile than the S&P 500.

Summary

BioMarin Pharmaceutical beats Sage Therapeutics on 11 of the 14 factors compared between the two stocks.

Sage Therapeutics (NASDAQ:SAGE) and Zai Lab (NASDAQ:ZLAB) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.

Earnings and Valuation

This table compares Sage Therapeutics and Zai Lab's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sage Therapeutics$6.87 million600.39$-680,240,000.00($13.38)-5.28
Zai Lab$12.98 million902.42$-195,070,000.00($3.03)-43.92

Zai Lab has higher revenue and earnings than Sage Therapeutics. Zai Lab is trading at a lower price-to-earnings ratio than Sage Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Sage Therapeutics has a beta of 2.23, indicating that its stock price is 123% more volatile than the S&P 500. Comparatively, Zai Lab has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500.

Insider and Institutional Ownership

81.3% of Zai Lab shares are owned by institutional investors. 4.8% of Sage Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Sage Therapeutics and Zai Lab's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sage Therapeutics-7,706.84%-63.81%-56.64%
Zai LabN/AN/AN/A

Analyst Ratings

This is a summary of current recommendations for Sage Therapeutics and Zai Lab, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sage Therapeutics010702.41
Zai Lab00503.00

Sage Therapeutics currently has a consensus target price of $80.50, indicating a potential upside of 13.94%. Zai Lab has a consensus target price of $159.00, indicating a potential upside of 19.49%. Given Zai Lab's stronger consensus rating and higher possible upside, analysts clearly believe Zai Lab is more favorable than Sage Therapeutics.

Summary

Zai Lab beats Sage Therapeutics on 10 of the 14 factors compared between the two stocks.


Sage Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Royalty Pharma logo
RPRX
Royalty Pharma
1.7$42.34-2.9%$16.43 billionN/A0.00Insider Selling
News Coverage
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$137.37-5.1%$16.07 billion$219.75 million-17.54Analyst Report
CureVac logo
CVAC
CureVac
0.6$81.33-2.7%$15.20 billionN/A0.00Decrease in Short Interest
Gap Down
Elanco Animal Health logo
ELAN
Elanco Animal Health
1.4$30.93-0.2%$14.60 billion$3.07 billion-54.26Analyst Upgrade
Analyst Revision
News Coverage
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
1.9$76.35-0.3%$13.88 billion$1.70 billion17.47Earnings Announcement
Analyst Report
Analyst Revision
Zai Lab logo
ZLAB
Zai Lab
1.4$133.07-5.7%$11.71 billion$12.98 million-43.92Analyst Revision
News Coverage
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
1.4$10.58-3.2%$11.56 billion$16.89 billion-2.87
Bausch Health Companies logo
BHC
Bausch Health Companies
1.7$31.90-2.1%$11.33 billion$8.60 billion-5.85Analyst Report
Analyst Revision
Grifols logo
GRFS
Grifols
1.2$15.42-3.8%$10.60 billion$5.71 billion13.77Analyst Report
High Trading Volume
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.5$61.78-1.4%$10.27 billion$2.32 billion51.06
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
1.6$62.52-2.2%$9.31 billion$40.56 million-18.33Analyst Report
Analyst Revision
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.6$181.00-4.4%$9.16 billion$3.34 million-23.51Earnings Announcement
Analyst Report
Analyst Revision
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.1$160.45-1.5%$9.04 billion$2.16 billion50.62Analyst Report
Increase in Short Interest
Analyst Revision
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.4$118.63-5.6%$7.94 billion$103.71 million-27.02Analyst Report
Insider Selling
News Coverage
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$143.45-6.6%$7.66 billion$14.98 million-17.47High Trading Volume
News Coverage
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.8$45.82-3.5%$7.33 billion$339.08 million-26.64Analyst Report
Analyst Revision
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.4$51.27-3.0%$7.22 billion$1.12 billion106.81Analyst Upgrade
Analyst Revision
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.5$69.56-8.5%$7.22 billion$87.99 million-82.81High Trading Volume
Gap Down
United Therapeutics logo
UTHR
United Therapeutics
1.9$160.34-1.8%$7.14 billion$1.45 billion15.17Analyst Report
Analyst Revision
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.5$214.17-0.3%$6.65 billion$311.33 million-124.52Decrease in Short Interest
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$82.16-6.0%$6.48 billion$380.83 million-10.51Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Allakos logo
ALLK
Allakos
1.7$113.14-1.6%$6.01 billionN/A-41.29Earnings Announcement
Analyst Upgrade
Insider Selling
Analyst Revision
News Coverage
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.9$34.07-6.7%$5.75 billionN/A0.00Earnings Announcement
Analyst Report
High Trading Volume
Analyst Revision
News Coverage
Galapagos logo
GLPG
Galapagos
1.3$84.88-3.0%$5.55 billion$1.00 billion-12.86Analyst Report
High Trading Volume
Gap Down
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$41.61-2.7%$5.47 billion$150,000.00-19.63Earnings Announcement
Analyst Revision
News Coverage
Perrigo logo
PRGO
Perrigo
2.6$40.57-1.8%$5.40 billion$4.84 billion-676.05Earnings Announcement
Analyst Revision
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$92.01-1.1%$5.33 billion$66.51 million16.98High Trading Volume
Gap Up
AVIR
Atea Pharmaceuticals
1.7$63.04-12.0%$5.21 billionN/A0.00Upcoming Earnings
High Trading Volume
Decrease in Short Interest
Schrödinger logo
SDGR
Schrödinger
1.5$72.59-36.6%$5.04 billion$85.54 million0.00High Trading Volume
Unusual Options Activity
Gap Up
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.9$103.09-8.3%$4.97 billionN/A-29.37Earnings Announcement
Analyst Upgrade
Analyst Revision
News Coverage
Emergent BioSolutions logo
EBS
Emergent BioSolutions
1.8$90.87-4.2%$4.84 billion$1.11 billion29.22Analyst Upgrade
Eidos Therapeutics logo
EIDX
Eidos Therapeutics
1.0$122.21-0.0%$4.75 billion$26.69 million-46.12
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
1.8$77.87-1.8%$4.67 billionN/A-6.35Earnings Announcement
Analyst Report
Insider Buying
Analyst Revision
News Coverage
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.5$71.51-2.4%$4.31 billion$806.43 million-10.13Analyst Report
High Trading Volume
News Coverage
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$124.95-3.9%$4.26 billion$26.52 million-11.01Earnings Announcement
Analyst Revision
News Coverage
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.3$22.38-4.7%$4.08 billion$114.62 million-9.02Earnings Announcement
Analyst Report
Analyst Revision
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$57.87-1.5%$4.07 billion$306.98 million-8.28Earnings Announcement
Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$27.86-7.7%$4.05 billion$204.89 million-34.83News Coverage
IMAB
I-Mab
1.1$55.55-10.2%$4.00 billion$4.31 million-1.92Analyst Report
High Trading Volume
News Coverage
Gap Up
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$57.21-9.0%$3.98 billion$36.13 million-85.39Earnings Announcement
Analyst Report
Insider Selling
Decrease in Short Interest
Analyst Revision
News Coverage
Gap Up
Insmed logo
INSM
Insmed
1.2$37.29-1.7%$3.84 billion$136.47 million-14.34Earnings Announcement
Analyst Report
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$45.65-0.3%$3.67 billionN/A-6.15Analyst Report
Arvinas logo
ARVN
Arvinas
1.9$71.08-6.9%$3.47 billion$42.98 million-27.77Earnings Announcement
Analyst Downgrade
Insider Selling
Unusual Options Activity
Analyst Revision
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.5$47.33-2.6%$3.29 billion$117.91 million-9.60Analyst Downgrade
Analyst Revision
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.6$117.76-3.3%$3.18 billionN/A-58.59Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
MorphoSys logo
MOR
MorphoSys
0.4$24.10-2.7%$3.17 billion$80.43 million114.77News Coverage
LEGN
Legend Biotech
1.2$23.55-9.5%$3.11 billion$64.39 million0.00Increase in Short Interest
FibroGen logo
FGEN
FibroGen
1.6$33.73-1.8%$3.09 billion$256.58 million-12.92Earnings Announcement
Analyst Downgrade
Unusual Options Activity
Analyst Revision
News Coverage
ALX Oncology logo
ALXO
ALX Oncology
2.1$81.22-3.3%$3.01 billionN/A0.00Decrease in Short Interest
News Coverage
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.1$67.22-3.2%$2.95 billion$421.03 million23.67Analyst Report
News Coverage
This page was last updated on 3/4/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.